PATENT CLAIM ANALYSIS

Application Number: 16012351
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["514", "183000"]

Abstract:
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Claim (Index 1):
A method of treating an exocrine pancreatic cancer, the method comprising intravenously administering to a human patient having an exocrine pancreatic cancer 60-80 mg/m 2  of irinotecan in an irinotecan liposome injection formulation having a total volume of 500 mL over about 90 minutes, in combination with a therapeutically effective amount of leucovorin and 5-fluorouracil, to treat the exocrine pancreatic cancer in the patient, the irinotecan liposome injection formulation comprising an irinotecan liposome having irinotecan encapsulated within a liposome comprising phosphatidylcholine, cholesterol, and a polyethyleneglycol-derivatized phosphatidyl-ethanolamine, and the irinotecan liposome having a diameter of approximately 80-140 nm.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.22857
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14851111', '15241128', '14406776', '14812950', '14844500']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8221242385509866
- 35 USC 102 Novelty (BERT): 0.6637001155244788
- Combined Prediction Score: 0.8062818262483359
- Mean Citation Score: 580.9896340000001
- Max Citation Score: 688.93396
- Similarity Product: 600.5156787623978

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test